Articles From This Issue
By Ron P. Gallemore, MD, PhD; Andrew Shyu, MD; and John R. Heckenlively, MD
Cover Stories: Greatest Hits
Retinitis pigmentosa (RP) is diagnosed in approximately one in every 4000 people, and it is one of the most common inherited retinal diseases in the world. It is character…
By Jonathan L. Prenner, MD, and Richard S. Kaiser, MD
Think about your daily routine. What is the role of music in your everyday life? Is it essential to your process or just a welcome piece of background noise? What songs wo…
Supplements and Inserts
By CARL D. REGILLO, MD
One of the key components of successful and safe retina surgery is the ability to engage target tissue while causing minimal or no disruption of adjacent tissue. Whether dissecting hyaloid near the retina, peeling a membrane, or performing core vitrectomy, the surgeon must be ever mindful of tractional forces and how much stress the intraocular maneuvers are placing on the retina-vitreous interface.
By Charles C. Wykoff, MD, PhD, moderator; Caroline R. Baumal, MD; David Eichenbaum, MD; and Chirag P. Shah, MD, MPH
The prevalence of diabetes is growing globally; as such the number of people affected by vision-threatening diabetic retinopathy (DR) is likewise expected to continue to increase. Prevent Blindness America has estimated more than 7.6 million people in the United States have DR as a result of their systemic disorder.1
By FIRAS M. RAHHAL, MD
The majority of my cases are operated using 23-gauge instrumentation using valved cannulas whenever possible. While I do use some 25-gauge, I prefer to use the technology with which I am most comfortable. I am not necessarily resistant to change; however, I have been getting very good results with my particular setup for over a decade, and so it is difficult for me to justify modifying my approach.
Physicians and researchers at the USC Roski Eye Institute have collaborated with other California institutions to show that a first-in-kind stem cell-based retinal implant is feasible for us…
GenSight Biologics Announces Topline Results from Phase 3 Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)
GenSight Biologics announced that a phase 3 study of GS010 (rAAV2/2-ND4) in patients with Leber hereditary optic neuropathy (LHON) failed to meet its primary endpoint, with sham-treated eyes demonstra…